迪哲医药：高瑞哲 和Birelentinib最新研究数据在第67届美国临床血液学会（ASH）发布

Core Viewpoint - The company DiZhe Pharmaceutical (688192) announced significant advancements in two innovative drugs at the 67th American Society of Hematology (ASH) conference, focusing on treatments for T-cell and B-cell lymphomas [1] Group 1: Drug Developments - The high-selectivity JAK1 inhibitor, Goli Siti Ni (generic name: Golisitini capsules), has made multiple new progressions in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has presented the latest clinical data for the treatment of B-cell lymphoma [1]